dcsimg
Introducing new solutions for needle-free injection technology

Easier, Safer and Less Painful Options for Diabetic Treatment

Introducing new solutions for needle-free injection technology

interface for insulin-delivery
Needle-free injection technology developed by QS Medical Technology Co., Ltd.

Leverkusen, September 11, 2018 - Imagine being able to treat diabetes without needles. For more than 114 million Chinese patients, it can be a reality. QS Medical Technology Co., Ltd. (QS), based in Beijing, has designed a new needle-free injection technology that is safe, highly-effective and more comfortable for patients with diabetes. The drug is injected at high pressure under the skin surface.

"We are focused on developing innovative medical products to make life a little easier, safer and more comfortable for millions of patients in China and around the world,” said Justin Zhang, Founder and General Manager for QS. “That’s why we have partnered with Covestro to produce high-quality, needle-free injectors to meet the needs of a growing number of patients with diabetes,” said Zhang.

"Our vision is to make the world a brighter place,” said Wang Xinyu, Sales Director for China, Healthcare Sector, Covestro. “For patients with diabetes, that means working to find solutions that push the boundaries of what is possible. Needle-free technology can provide patients with a more comfortable, efficient injection experience and help increase medication compliance.”

Proven plastic for medical technology
Based on its previous experience in the area of needle-free injection, QS selected Makrolon® Rx1805, a medical-grade polycarbonate from Covestro, for the medicine ampoules. Makrolon® medical-grade polycarbonates have excellent properties of durability, processability, safety and design flexibility, which meet the stringent requirements of a wide variety of medical products. With superior material performance, Covestro provides QS with total material solutions for its needle-free syringe products.


Makrolon® Rx1805 polycarbonate is used in the production of the insulin-delivery interface and for molding the ampoules.

"Makrolon® Rx1805 polycarbonate is mainly used in the production of the insulin-delivery interface and for molding the ampoules containing the medication for needle-free syringe products," said Su Ning, head of QS Product Center. "The material meets our requirements for the plastic drug-delivery components and ampoule bottles for precise size, high strength and toughness. It ensures that the drug-delivery component can consistently and safely puncture through the plug of an insulin ampoule and fulfills our design, so that the drug-sampling needle and the protective cover of the drug suction apparatus are manufactured in one shot via injection molding."

Tailor-made properties
The main benefits of Makrolon® Rx1805 polycarbonate from Covestro are:

  • Resistant to cracking against lipids
  • Resistant to radiation sterilization and able to ensure high productivity and efficiency during the molding of the ampoule bottles
  • Biocompatible and complies with multiple requirements of ISO 10993
  • High impact resistance
  • Accuracy in molding size, and able to maintain stability under different application environments

“Our Research and Development goal for the next decade is to integrate injection drug with needle-free technology, and launch more convenient pre-loaded, needle-free administration systems to the market,” said Zhang. “To do this, we hope to develop a collaborative partnership with Covestro to push the boundaries in technology innovation for needle-free injection."  

LOCATIONS & CONTACTS
Login
Register for more information
Forgot your password?
CAN WE HELP YOU?
CAN WE HELP YOU?
Feel free to contact us more »